Alerta

MEDICAL HYDROGEL CONTAINING ULTRASONICALLY-IMAGEABLE BUBBLE MICROSPHERES AND PREPARATION METHOD THEREOF

Resumen de: US2025367331A1

Provided are a medical hydrogel containing ultrasonically-imageable bubble microspheres and a preparation method thereof. The medical hydrogel containing the ultrasonically-imageable bubble microspheres is formed by in-situ crosslinking of a polyethylene glycol precursor solution and a poly-amino crosslinker solution containing bubble microspheres, the polyethylene glycol precursor solution consisting of a multi-arm polyethylene glycol derivative and a buffer solution A.

ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME

Resumen de: US2025367305A1

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

POLYMER NANOPARTICLE COMPOSITIONS FOR NON-VIRAL GENE DELIVERY

Resumen de: WO2025250979A1

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

PROCESS FOR PREPARATION OF TARGETED LIPID NANOPARTICLES

Resumen de: WO2025250906A1

The present invention relates to processes for preparing lipid nanoparticles having an antibody or fragment antibody binding region.

LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: WO2025250729A1

The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: WO2025250730A1

The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

COMPOSITION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA

Resumen de: WO2025248434A1

A composition for topical use in the treatment of androgenetic alopecia comprises a nanoemulsion, said nanoemulsion comprising a mixture of oils, at least one surfactant, finasteride and minoxidil. The mixture of oils comprises sandalwood oil, rosemary oil and sweet almond oil.

NANOPARTICLES FOR ADMINISTERING AN ACTIVE INGREDIENT

Resumen de: WO2025247930A1

Nanoparticles (1) for administering at least one active ingredient (4), said nanoparticles comprising a magnetizable core (2), the core (2) having a shell (3) made of a polyphosphate and said shell (3) completely enclosing the core (2), characterized in that the shell (3) is mixed with an active ingredient (4).

DEXTRAN NANOPARTICLES FOR T-CELL ACTIVATION AND PROLIFERATION

Resumen de: WO2025247992A1

The invention relates to antigen-functionalized dextran-based nanoparticles capable of activating, functionally modifying, re-programming, and stimulating expansion of T cells, A pharmaceutical comprising the nanoparticles find use in the treatment of a medical condition requiring the activation and/or expansion of T-cells and/or in the production of receptor engineered-T cells used in such treatments.

METHOD FOR THE PRODUCTION OF EXTRACELLULAR VESICLES LOADED WITH A MOLECULE OF INTEREST AND COMPOSITION COMPRISING SUCH EXTRACELLULAR VESICLES

Resumen de: WO2025247999A1

Method for the production of extracellular vesicles, EVs, loaded with a molecule of interest in a bioreactor containing a porous three-dimensional, 3D, scaffold, wherein the method comprises a seeding of the scaffold with a starting number of adherent immortalized cells resuspended after detachment, an attachment of the cells on said scaffold, an expansion of the cells on said scaffold up to a second number of adherent cells, defining a multiplication factor of at least 5 for a single expansion step, a production of EVs by said cells, a phase of loading said EVs with said molecule of interest, a harvest of EVs.

INJECTABLE COMPOSITIONS OF EMD FRACTION B

Resumen de: WO2025247843A1

The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 60-7.5. Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.

METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE

Resumen de: US2025367275A1

The present disclosure provides methods for treating an individual with pancreatic cancer with an individualized cancer vaccine and a PD-1 axis antagonist.

MIXTURES OF LIPID NANOPARTICLES AND CELL PENETRATING PEPTIDES

Resumen de: WO2024156871A1

The present invention provides for a membrane-permeable construct for transport of cargo across a lipid membrane and subsequent delivery of cargo into cells as well as in vivo, wherein the construct comprises a Lipid nanoparticle (LNP) complexed with known or proprietary cell penetrating peptide (CPP) embedding the cargo molecule.

浮腫性線維硬化性脂肪組織異常を治療及び／又は予防するための方法

Resumen de: CA3272967A1

It provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject an effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.

INJECTABLE COMPOSITIONS OF EMD FRACTION B

Resumen de: EP4656213A1

The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 6.0-7.5.Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.

NANOPARTICLES FOR THE DELIVERY OF AN ACTIVE AGENT

Resumen de: EP4656180A1

Nanoteilchen (1) zur Verabreichung zumindest eines Wirkstoffs (4), umfassend einen magnetisierbaren Kern (2), wobei der Kern (2) eine Ummantelung (3) aus einem Polyphosphat aufweist, wobei die Ummantelung (3) den Kern (2) vollständig umschließt, dadurch gekennzeichnet, dass die Ummantelung (3) mit einem Wirkstoff (4) versetzt ist.

A METHOD FOR THE PRODUCTION OF POLYPRENOL NANOEMULSION AND THE POLYPRENOL NANOEMULSION OBTAINED

Resumen de: WO2025034098A1

A method for the production of a polyprenol nanoemulsion involving: - mixing of polyprenols with divalent alcohol in a mass ratio of 1:0.5-2; - the addition of an emulsifier containing polyethylene glycol sorbitan monooleate at a proportion of 50-100% of the mixture of polyprenols and divalent alcohol by mass; - mixing and heating of the resulting mixture for 5-15 minutes at a temperature of 70-80 °C; - dissolving NaCI in water, adding glucose, previously prepared phosphate buffer solution with the pH 6.88 and divalent alcohol, and mixing; - mixing and heating of the resulting aqueous mixture for 5-15 minutes at a temperature of 70-80 °C. A polyprenol nanoemulsion comprising by mass%: polyprenols 2.5-10; emulsifier that contains polyethylene glycol sorbitan monooleate 7-8; divalent alcohol 8-12; NaCI 0.9; glucose 5; phosphate buffer solution with pH 6.88 8-12; water, the rest.

COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER

Resumen de: EP4656628A1

An object of the present invention is to provide a compound or a salt thereof constituting lipid composition that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide a lipid composition, a pharmaceutical composition, and a delivery carrier, using the compound or a salt thereof. According to the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, R¹, R², R³, and R⁴ each independently represent a hydrogen atom or a hydrocarbon group having 1 to 24 carbon atoms, which may be substituted, R⁵ and R⁶ each independently represent a hydrocarbon group having 1 to 18 carbon atoms, which may be substituted, R⁷, R⁸, and R⁹ each independently represent a hydrocarbon group having 2 to 8 carbon atoms, and R⁵ and R⁶, or R⁵ and R⁷, may be combined to form a 4- to 7-membered ring.

METHODS OF MAKING AND ISOLATING CIRCULAR RNAS AND CIRCULAR RNA COMPOSITIONS

Resumen de: AU2024211148A1

Provided herein is a method of making circular RNA, a method of isolating circular RNA and compositions comprising circular RNA.

Ｃ１～Ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）とコンジュゲートした脂質

Resumen de: MX2025005655A

The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.

A MODIFIED LIPID COMPOSITION AND USES THEREOF

Resumen de: AU2024212425A1

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.

ポリオキシアルキレンがＣ１～Ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）である、ポリオキシアルキレン－１，２－ジミリストイル－グリセロール化合物

Resumen de: MX2025005575A

The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.

脂質化合物およびその使用

Resumen de: US2025367129A1

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

ＴＧＦ－β１ワクチン

Resumen de: MX2025005144A

The present invention relates to novel polypeptides, which are derived from transforming growth factor beta 1 (TGFβ1; TGFb-1) as well as polynucleotides encoding such polypeptides and compositions comprising such peptides. The present invention is further concerned with ways to increase the selectivity of the immune response to TGFb-1. The invention also concerns uses, and methods of using, said polypeptides, polynucleotides, and compositions.

アミド及びエステル官能基を有する脂質及びその製造方法

Nº publicación: JP2025538957A 03/12/2025

Solicitante:

サムヤン、ホールディングス、コーポレーション

Resumen de: CN120019041A

The present invention relates to a lipid having an amide functional group and an ester functional group and a method for preparing the same, and more particularly, to an ionized lipid which forms a complex with an anionic drug, and which can be used for drug delivery due to a specific structure having an amide functional group and an ester functional group, and a method for preparing the same.